Researchers sought to determine whether home nursing based on smart medical Internet of Things systems could improve the quality of life of patients with hemophilia.
Researchers sought to determine whether biases were present in clinical trials included in the package inserts of coagulation factors used for the treatment of hemophilia.
Researchers sought to determine whether rVIII-SingleChain therapy would be safe and effective as a long-term prophylaxis option for previously treated patients with hemophilia A.
Researchers sought to determine whether efanesoctocog alfa may yield high sustained FVIII activity and improve bleed protection in patients with severe hemophilia A.
In preclinical studies, ASC618 has been shown to have at least a 10-fold increase in the biosynthesis and secretion of FVIII compared with native human FVIII bioengineered constructs.
The phase 3 GENEr8-1 study evaluated valoctocogene roxaparvovec in adults with severe hemophilia and residual FVIII levels less than or equal to 1 IU/dL.
Researchers sought to develop a booklet for parents of children with hemophilia to help them manage physical activity restrictions based on the self-determination theory.
Researchers sought to determine whether ITI therapy with ADVATE® would be safe and effective in patients with hemophilia A and neutralizing antibodies to coagulation factor VIII.
Researchers sought to determine whether patients with hemophilia A would be at higher risk of bleeding events when participating in high-collision physical activity.
Researchers sought to determine whether switching to EHL factor concentrates would have an impact on health-related quality of life for patients with hemophilia.
Researchers sought to determine whether the neurodynamics nerve flossing technique would be beneficial in the treatment of femoral neuropathy in children with hemophilia.
Researchers sought to determine whether a novel variant of activated human factor VII Marzeptacog alfa (activated) would be effective as prophylactic treatment in patients with severe congenital hemophilia with inhibitors.
Researchers sought to determine whether clearer guidelines are needed for utilizing ultrasounds to assess musculoskeletal outcomes in patients with hemophilia.
Researchers sought to determine whether combined training would improve lipid profiles and quality of life in patients with hemophilia A who were overweight.
People with hemophilia tend to have less adherence to prophylaxis as they transition to adulthood but continuing the therapy can improve their joint health.
Researchers sought to determine whether plasma-derived von Willebrand factor/factor VIII would be safe and effective in patients with hemophilia A younger than 12 years.
Researchers sought to determine whether recombinant VWF would be effective in reducing spontaneous bleeding for patients with severe VWD previously treated in an on-demand manner.
Researchers sought to determine whether valoctocogene roxaparvovec would reduce the risk of bleeding and rate of factor VIII infusion in patients with hemophilia A.
Acquired hemophilia A (AHA) and acquired von Willebrand syndrome (aVWS) are rare, life-threatening bleeding disorders that occur in patients with no bleeding history and no family history of a bleeding disorder.
Researchers sought to determine whether transfusing ABO-incompatible platelets would lead to worse clinical outcomes and slower platelet recovery in patients with ICH.